155 related articles for article (PubMed ID: 27569188)
1. Cancer heterogeneity determined by functional proteomics.
Szász AM; Győrffy B; Marko-Varga G
Semin Cell Dev Biol; 2017 Apr; 64():132-142. PubMed ID: 27569188
[TBL] [Abstract][Full Text] [Related]
2. Four areas of engagement requiring strengthening in modern proteomics today.
Fehniger TE; Boja ES; Rodriguez H; Baker MS; Marko-Varga G
J Proteome Res; 2014 Dec; 13(12):5310-8. PubMed ID: 25405748
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
5. Deciphering lymphoma pathogenesis via state-of-the-art mass spectrometry-based quantitative proteomics.
Psatha K; Kollipara L; Voutyraki C; Divanach P; Sickmann A; Rassidakis GZ; Drakos E; Aivaliotis M
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Mar; 1047():2-14. PubMed ID: 27979587
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer.
Murray HC; Dun MD; Verrills NM
Expert Opin Drug Discov; 2017 May; 12(5):431-447. PubMed ID: 28286965
[TBL] [Abstract][Full Text] [Related]
7. Emerging applications for phospho-proteomics in cancer molecular therapeutics.
Moran MF; Tong J; Taylor P; Ewing RM
Biochim Biophys Acta; 2006 Dec; 1766(2):230-41. PubMed ID: 16889898
[TBL] [Abstract][Full Text] [Related]
8. Proteomic Approaches for Biomarker Panels in Cancer.
Tanase C; Albulescu R; Neagu M
J Immunoassay Immunochem; 2016; 37(1):1-15. PubMed ID: 26565430
[TBL] [Abstract][Full Text] [Related]
9. In-depth proteomics of ovarian cancer ascites: combining shotgun proteomics and selected reaction monitoring mass spectrometry.
Elschenbroich S; Ignatchenko V; Clarke B; Kalloger SE; Boutros PC; Gramolini AO; Shaw P; Jurisica I; Kislinger T
J Proteome Res; 2011 May; 10(5):2286-99. PubMed ID: 21491939
[TBL] [Abstract][Full Text] [Related]
10. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
Lee JW; Figeys D; Vasilescu J
Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
[TBL] [Abstract][Full Text] [Related]
11. Advances in clinical applications of tissue proteomics: opportunities and challenges.
Dogan A
Expert Rev Proteomics; 2014 Oct; 11(5):531-3. PubMed ID: 25187078
[TBL] [Abstract][Full Text] [Related]
12. Clinical proteomics in cancer: Where we are.
Panis C; Pizzatti L; Souza GF; Abdelhay E
Cancer Lett; 2016 Nov; 382(2):231-239. PubMed ID: 27561426
[TBL] [Abstract][Full Text] [Related]
13. Proteomics in the Assessment of the Therapeutic Response of Antineoplastic Drugs: Strategies and Practical Applications.
Torres VM; Popovic L; Vaz F; Penque D
Methods Mol Biol; 2016; 1395():281-98. PubMed ID: 26910080
[TBL] [Abstract][Full Text] [Related]
14. Oncoproteomics: Current status and future opportunities.
He Y; Mohamedali A; Huang C; Baker MS; Nice EC
Clin Chim Acta; 2019 Aug; 495():611-624. PubMed ID: 31176645
[TBL] [Abstract][Full Text] [Related]
15. Role of oncoproteomics in the personalized management of cancer.
Jain KK
Expert Rev Proteomics; 2004 Jun; 1(1):49-55. PubMed ID: 15966798
[TBL] [Abstract][Full Text] [Related]
16. Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.
Zhou L; Wang K; Li Q; Nice EC; Zhang H; Huang C
Expert Rev Proteomics; 2016; 13(4):367-81. PubMed ID: 26923776
[TBL] [Abstract][Full Text] [Related]
17. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
Findeisen P; Neumaier M
Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
[TBL] [Abstract][Full Text] [Related]
18. Translational proteomics: developing a predictive capacity -- a review.
Rice GE; Georgiou HM; Ahmed N; Shi G; Kruppa G
Placenta; 2006 Apr; 27 Suppl A():S76-86. PubMed ID: 16434096
[TBL] [Abstract][Full Text] [Related]
19. Role and challenges of proteomics in pharma and biotech: technical, scientific and commercial perspective.
Qoronfleh MW
Expert Rev Proteomics; 2006 Apr; 3(2):179-95. PubMed ID: 16608432
[TBL] [Abstract][Full Text] [Related]
20. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
Lin F; Li Z; Hua Y; Lim YP
Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
